Audio Coursesby JellypodLesson 15 of 15
Overview
Jeremy and Hamish expertly dissect the latest evidence in cardiac arrest management. From high-performance CPR to pragmatic drug strategies, they spotlight what matters most in improving survival. No hype—just the distilled principles and pitfalls frontline clinicians need to master.
Hamish: Welcome back to the TIME Podcast, where we dive into the latest in critical care, resuscitation, and everything in between. I'm Hamish, and today, we're talking about some major updates in cardiac arrest management. Joining me as always is Jeremy. Jeremy, how are you doing today?
Jeremy: I'm great thanks. Excited to get into this one. Cardiac arrest management is one of those areas that never stands still, right? Every year, we see new evidence and shifts in practice. So much to unpack today, from high-performance CPR to innovations in drug therapy. It’s going to be a fascinating discussion.
Hamish: Definitely. And with all these changes, it's easy to get lost in the details. But today, we’re going to focus on what's truly changed in both out-of-hospital and in-hospital cardiac arrest care. We’ll dive into the biggest updates, the ongoing controversies, and, importantly, how expert clinicians should interpret and implement the latest evidence.
Hamish: Let’s start with high-performance CPR. We’ve seen a lot of emphasis over the years on the importance of compression fraction and minimizing interruptions, right? These have proven to be the most powerful modifiable factors in survival. But what does the evidence actually tell us?
Jeremy: Absolutely. So, compression fraction has become the single most important metric for improving survival outcomes. The data is pretty clear—compressions need to be at 80% or higher. But here’s the kicker: even in well-functioning systems, in-hospital cardiac arrest (IHCA) often suffers from poor compression fractions due to procedural complexity, multiple competing priorities, and team coordination failures. This is something that’s often overlooked, but it directly impacts survival rates.
Hamish: That’s where structured CPR systems come into play. We’ve seen great improvements in compression fraction when hospitals adopt structured, choreographed bundles. And I mean choreographed in the sense of everything being planned—role assignments, pre-briefing, and having a CPR coach on the team whose sole focus is compression quality and minimizing pauses.
Jeremy: Exactly. What’s fascinating is the way real-time feedback integrates into these bundles. CPR feedback devices can significantly improve metrics, but they’re most effective when paired with hot and cold debriefing. After the code, teams review the logs, and everyone gets the chance to give and receive feedback in real time. That reflection really drives continuous improvement. Without that structured feedback loop, all the devices in the world won’t make a difference.
Hamish: Right. So, when we talk about system improvements, it’s not just about the equipment or the guidelines—it’s about how these practices are embedded into daily workflows. If you’re not doing regular debriefs and process reviews, your team can’t evolve and improve.
Jeremy: Now, let’s move on to mechanical CPR. This is an area with some mixed opinions. The big trials show no clear superiority of mechanical devices over manual CPR when it comes to neurologically intact survival. But that doesn’t mean mechanical CPR is without its place, right?
Hamish: Exactly. Mechanical CPR is useful in prolonged resuscitations, retrieval situations, and unsafe environments where it might be hard to perform manual CPR. For instance, when you’re transporting a patient from a rural area to a tertiary hospital, mechanical CPR can help keep the patient stable during the journey without tiring out the team.
Jeremy: That's right. It's not about the device itself being superior—it’s more about workflow advantages. For instance, safe transport during retrieval or ECPR cannulation becomes much easier when you have mechanical CPR, which allows the team to focus on other tasks without worrying about maintaining compressions. It's also crucial when you're in confined spaces or facing safety concerns.
Hamish: But here's where we need to be careful—mechanical CPR should be protocol-driven, not a catch-all solution. When used indiscriminately, it can actually be counterproductive. And, let’s face it—deployment pauses can actually be harmful if not carefully managed.
Jeremy: Exactly. The key takeaway here is selective use—we need to use these devices in the right context, especially for situations where manual CPR might not be feasible or safe. The protocolization of mechanical CPR in retrieval or prolonged resuscitations is what’s making the biggest difference.
Hamish: Now, let’s shift gears to airway management. The big question has been whether supraglottic airways (SGAs) should replace endotracheal intubation (ETI), especially for out-of-hospital cardiac arrest (OHCA). Studies like AIRWAYS-2 and PART have shown no clear survival benefit for ETI over SGAs, but is that the whole story?
Jeremy: Not quite. The OHCA trials suggest that SGAs-first strategies work well in the field because they’re faster to place and lead to fewer interruptions. But when we get into the IHCA setting, ETI has more of a role—if it’s done properly. In a controlled hospital environment, ETI can still provide superior airway protection, especially in patients with head trauma, aspiration risk, or severe airway obstruction.
Hamish: So, it’s really about context. In field settings, you want speed and minimal disruption, which is where SGAs excel. But in hospital settings, where we have more control and skilled operators, ETI is still a valid choice—provided we don’t overextend attempts and compromise CPR quality.
Jeremy: Now, let’s talk about drugs. Adrenaline has long been the go-to for non-shockable rhythms, but what about for shockable rhythms? There’s still a lot of debate around the timing and frequency of adrenaline administration.
Hamish: Right, the data’s clear that adrenaline in non-shockable rhythms improves ROSC, but does it improve long-term survival? When we get into shockable rhythms, the evidence is less clear. Early doses seem to help with ROSC, but we don’t have strong evidence yet that they lead to better outcomes in terms of neurological survival. Timing is still controversial, and some experts argue that repeated doses could have diminishing returns.
Jeremy: And then there’s the amiodarone vs lidocaine debate. Amiodarone has been the go-to for refractory VF, but lidocaine is gaining traction. The recent studies show that both drugs are essentially equally effective—with no difference in long-term survival. Yet, hospitals often stick with amiodarone due to institutional preference, availability, or familiarity.
Hamish: One important takeaway is that routine use of calcium and bicarbonate is being phased out. These drugs have very specific uses now—like in hyperkalemia, TCA toxicity, or calcium channel blocker toxicity. For most other cases, they’re on the “do-not-use routinely” list.
Hamish: Let’s dive into defibrillation innovations. Vector-change defibrillation has shown to improve outcomes in refractory VF. The idea is simple—switch the pad positions after 2-3 failed shocks to increase the likelihood of shock success. But then there’s Double Sequential External Defibrillation (DSED). Is this something we should adopt more widely?
Jeremy: DSED has real promise for patients with refractory VF, especially those who don’t respond to standard defibrillation. But it’s not for everyone. Two defibrillators are needed, and you require highly trained teams. It’s very specialized. For most hospitals, vector-change defibrillation is the go-to strategy. It’s quick, effective, and doesn’t require the logistical challenges of DSED.
Hamish: And let’s not forget that minimizing peri-shock pauses is critical. In many hospitals, we’re seeing charging during compressions and shocking hands-on to reduce those pauses. It’s becoming more achievable, especially with the right protocols and training.
Hamish: Let’s talk about ECPR—extracorporeal CPR. This has become a growing area of interest, especially for patients who are refractory to conventional resuscitation efforts. The evidence is growing, but we know that it’s only beneficial in a very specific group of patients—witnessed arrest, shockable rhythms, immediate bystander CPR, and low-flow times under 60 minutes.
Jeremy: That’s right. ECPR is not a universal fix. The patient must meet very strict criteria—otherwise, the outcomes won’t be any better than standard resuscitation. And the system needs to be in place to support it. ECPR requires rapid activation, safe transport, and coordinated teams for cannulation and perfusion. Without that, it’s not going to make a difference.
Hamish: And here’s the thing—regionalization of care is key. Major urban centers in cities like Sydney, Melbourne, and Brisbane have well-established ECPR pathways, but we still face significant barriers in rural and remote areas. Without these systems, even the best technology won’t save lives.
Jeremy: Exactly. The logistics are paramount. ECPR might be a life-saving intervention for those who meet the criteria, but if the system can’t support the timely delivery of care, it’s essentially useless. This is why system-level planning and regional coordination are so important.
Hamish: Let’s move to a critical phase of cardiac arrest management: Post ROSC care. This phase, which begins once the heart starts beating again, is just as important as the initial resuscitation. Post ROSC care has evolved significantly, especially in terms of neurological protection and hemodynamic support. Jeremy, what’s the current approach in this phase?
Jeremy: Post ROSC care has really shifted toward targeted interventions aimed at improving neurological outcomes and ensuring hemodynamic stability. The goal is to prevent further ischemic injury and ensure adequate organ perfusion. The first thing we need to talk about is temperature management.
Hamish: Temperature management has been a hot topic in recent years, especially after the TTM2 trial. We used to focus heavily on induced hypothermia, but that’s changed now, hasn’t it?
Jeremy: Exactly. The TTM2 trial was a game-changer. It showed that active normothermia—keeping patients at around 36°C—is as effective, if not better, than targeting lower temperatures (32-34°C). The key takeaway is that deep hypothermia isn’t the answer anymore, because it can lead to complications like infection, bleeding, and arrhythmias. Now, normothermia is the new standard, and the focus is on preventing fever after ROSC. Fever is a major risk factor for poor neurological outcomes.
Hamish: That makes sense. So, it’s not about cooling patients to extremes anymore, but ensuring that we avoid hyperthermia at all costs. How do we manage that in a practical, clinical sense?
Jeremy: We now use continuous temperature monitoring in most post-ROSC patients. This helps us avoid any unintended hyperthermia, which is associated with worse neurological outcomes. Patients are often sedated and paralyzed to facilitate controlled ventilation and to prevent shivering, which can elevate body temperature. Antipyretics are also used to keep the patient at the desired temperature.
Hamish: In terms of oxygenation, we know that hyperoxia can lead to brain injury, right? So, what’s the current guideline on oxygen levels?
Jeremy: Yes, hyperoxia is a major concern. The goal is to keep the SpO₂ levels between 92-96%, which translates to a PaO₂ range of about 60-100. Anything higher than that, and you increase the risk of cerebral injury due to oxidative stress. The key point is normoxia—we want to avoid both hypoxia and hyperoxia to optimize cerebral and systemic perfusion.
Hamish: And ventilation is also a critical piece, right? We want to make sure we’re not ventilating too aggressively.
Jeremy: Exactly. The days of permissive hypercapnia are over. We now aim for normocapnia—a PaCO₂ between 35-45 millimeters of mercury—because high CO₂ levels can increase intracranial pressure and worsen cerebral ischemia. This is particularly relevant in post-cardiac arrest patients who may already have significant cerebral edema.
Hamish: Now, let’s talk about the hemodynamics of post ROSC care. Maintaining adequate perfusion pressure is crucial. The target for mean arterial pressure (MAP) is more than or equal to 65 millimeters of Mercury, but this can be adjusted for patients with pre-existing hypertension. Can you tell us more about that?
Jeremy: Absolutely. The MAP of more than or equal to 65 target is the standard, but patients with chronic hypertension may need higher MAPs to ensure adequate perfusion. It’s all about individualizing care. If a patient has been chronically hypertensive, their baseline perfusion pressure is probably higher, so targeting a higher MAP may be required to ensure adequate perfusion to vital organs.
Hamish: And what about early coronary angiography? That’s another important aspect of post-ROSC care, isn’t it?
Jeremy: Definitely. Early coronary angiography is now a key part of post-ROSC management, especially in patients with persistent shock or those showing ECG signs of acute coronary occlusion. The COVERSA trial and other recent studies have shown that early intervention—including PCI (percutaneous coronary intervention)—improves outcomes in cardiac arrest survivors. If we suspect STEMI or acute coronary occlusion, we’re now moving towards immediate angiography. For patients who present with STEMI, early PCI can dramatically improve long-term survival and neurological recovery.
Hamish: That’s critical, especially given how often myocardial infarction is the underlying cause of arrest. But what about patients who don’t have a coronary cause for their arrest? How does the approach differ?
Jeremy: That’s a great point. For patients without a clear cardiac cause for arrest, post-ROSC care still involves the basics of neurological protection, but we might de-escalate some of the more aggressive interventions, like early angiography, if the cause isn’t related to the heart. However, neuroprognostication becomes a major part of the equation.
Hamish: Ah, neuroprognostication—that's crucial. How do we approach that in the immediate post-ROSC phase?
Jeremy: This is where things get tricky. Prognostication is a delicate process, and it’s something we do carefully, often waiting 72 hours before making definitive decisions about neurological outcomes. We use tools like neurological exams, EEG, and CT scans to assess brain injury and potential recovery. The key is avoiding premature conclusions. Temperature control and sedation can affect assessments, so we need to wait until patients are stable before we make any decisions.
Hamish: So, we’re talking about a multidisciplinary approach—involving neurologists, intensivists, and cardiologists—to ensure we’re addressing both neurological and cardiovascular aspects of post-ROSC care.
Jeremy: Exactly. And we can’t forget about team communication. Multidisciplinary rounds are essential in these cases, ensuring that everyone is on the same page regarding the prognosis, goals of care, and next steps.
Hamish: Before we wrap up today’s episode, let's dive into some of the systems-level considerations—because, as we know, clinical interventions don’t exist in a vacuum. Cardiac arrest management doesn’t just depend on individual decisions or even single institutions, but also on how the whole system works together to deliver timely, high-quality care. Jeremy, we’ve talked about the latest clinical interventions, but let’s zoom out and look at the broader systems that influence these decisions.
Jeremy: That’s exactly right, Hamish. The systems-level issues are often where the biggest gaps exist. Clinical teams can be highly skilled, but without the right infrastructure, training, and resources, those teams can be hindered in delivering optimal care. Let's start with the urban-rural disparity—it’s a huge challenge, especially in a vast country like Australia.
Hamish: Yes, absolutely. Larger cities like Sydney, Melbourne, and Brisbane are equipped with advanced technologies, such as ECPR and mechanical CPR, and they have systems set up for quick retrieval and transport. But in rural and remote areas, access to these technologies is often limited, and that can mean a significant difference in outcomes for patients who suffer a cardiac arrest. So, how do we begin to address this disparity?
Jeremy: It starts with regionalized care models—and this is something we’re seeing increasingly in major hospitals across urban areas. These models are built on the idea that regional hubs provide specialized services like ECPR, mechanical CPR, and advanced post-ROSC care, while smaller rural hospitals focus on stabilization and timely transfer. We’ve seen this model work well in places like Melbourne and Auckland, but it requires a robust network of retrieval services and close collaboration between hospitals.
Hamish: Right, it’s about ensuring that rural hospitals aren’t isolated—they need to be part of a larger network where they can safely stabilize patients, knowing they have clear protocols for transfer to higher-level centers. This needs to be more than just transportation—it should be a coordinated effort across the system.
Jeremy: Exactly. A key factor in this is pre-hospital care—paramedics and retrieval teams need to have access to the best tools for early intervention. The earlier that quality CPR or defibrillation is initiated, the better the outcome. But we’re not just talking about equipment—it’s also about training. Rural paramedics often face challenges in getting the same level of specialized training as their city counterparts.
Hamish: That’s a good point. And speaking of training, this is another critical system-level issue—there are standardized protocols, but not all regions have the same access to high-quality education and simulation training. How do we standardize that training across different regions?
Jeremy: One solution is to make advanced training more accessible through telemedicine or simulation networks. For instance, some hospitals are now using telemedicine platforms to consult with specialists in real-time during critical care scenarios. This has allowed remote hospitals to leverage the expertise of city-based doctors for things like airway management, advanced defibrillation techniques, or ECPR decisions.
Hamish: That’s a great example of systems integration—using technology to bridge gaps and make specialized care more accessible. But there are also structural challenges in how these systems are set up. For example, many hospitals in rural areas don’t have the personnel or resources to handle long resuscitation efforts, especially for prolonged cardiac arrest cases. How do we address this?
Jeremy: Well, it’s about improving resource allocation. Rural hospitals need better staffing models—more specifically, the right level of specialized staff—who can manage these complex cases. Many hospitals are adopting flexible staffing that allows ICU specialists or advanced life support teams to travel between rural hospitals and provide that extra layer of expertise. But the real challenge is sustainability—making sure these systems are in place long term, with appropriate funding and logistics to keep them operational.
Hamish: That’s where equity becomes such a huge factor. If you’re in an underserved area, it’s not just about the technology—it’s also about ensuring that access to skilled professionals and timely interventions is not determined by your zip code or socioeconomic status. We need to ensure that rural hospitals have the same high standards as their urban counterparts.
Jeremy: And we can’t forget about data and performance tracking—national registries, like ANZROD and Aus-ROC, are huge assets in tracking performance across systems. By using these tools, we can identify areas of inequity—for example, by tracking survival rates or time-to-treatment metrics across different regions—and make the case for system-level improvements in areas that are underperforming.
Hamish: Absolutely. And what about community outreach and awareness? Bystander CPR can be the difference between life and death in the first few minutes of an arrest. We need to educate the public and get more people trained in basic life support skills, don’t we?
Jeremy: You’re spot on. Public awareness is critical, especially in rural communities where the population may not have the same familiarity with cardiac arrest management as urban areas. Some regions are investing in community CPR programs and first responder training to ensure that people know how to respond when someone goes into cardiac arrest. This could dramatically improve early survival rates and reduce the time to defibrillation, which we know is crucial.
Hamish: And finally, I think it’s clear that improving systems isn’t just about infrastructure or technology—it’s about the collaboration of everyone involved in the process: from paramedics to ICU staff to hospital administrators. Everyone needs to be working together to ensure that the right decisions are made at the right time, with the best tools available.
Jeremy: Exactly, it’s a team sport—and the more we can integrate across different parts of the healthcare system, the better outcomes we’ll see. But it takes a coordinated effort and investment at all levels—government, hospital networks, and individual healthcare providers.
Hamish: Alright, that’s probably a good place to stop. Hopefully we’ve given you a clear-eyed look at what really counts in cardiac arrest management, what’s newish, and what’s still, well, not quite ready for primetime.
Jeremy: Absolutely—keep focusing on high-quality basics, and don’t get distracted by the shiny stuff unless the evidence is there. We’ll be back to dig into more practical essentials in critical care soon enough.
Hamish: Thanks as always, Jeremy, and thank you folks for tuning in. Take care of yourselves.
Jeremy: Cheers Hamish—and thanks everyone, see you next episode on the TIME Podcast.
